Orion Oyj (OTCMKTS:ORINY) Issues Earnings Results

Orion Oyj (OTCMKTS:ORINY) issued its quarterly earnings results on Tuesday. The company reported $0.28 earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $463.41 million for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%.

Orion Oyj Price Performance

Shares of ORINY opened at $27.03 on Thursday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. Orion Oyj has a 52 week low of $17.50 and a 52 week high of $28.55. The stock has a market capitalization of $7.63 billion, a price-to-earnings ratio of 21.45 and a beta of 0.24. The stock has a fifty day moving average of $24.83 and a 200-day moving average of $25.12.

Analysts Set New Price Targets

Separately, Nordea Equity Research downgraded shares of Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.